Abstract The oncogenic Bcr-Abl tyrosine kinase activates various signaling pathways
including phosphoinositide 3-kinase/Akt and nuclear factor-κB that mediate proliferation …

The tyrosine kinase inhibitor (TKI) imatinib has resulted in excellent responses in the
majority of Chronic Myeloid Leukaemia (CML) patients; however, resistance is observed in …

The paradigm of targeted therapy was pioneered for chronic myeloid leukemia (CML). The
advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and …

The current status of peptides that target the mitochondria in the context of cancer is the
focus of this review. Chemotherapy and radiotherapy used to kill tumor cells are principally …

The effect of ABT‐737, a BH3‐mimicking inhibitor for anti‐apoptotic Bcl‐2 and Bcl‐XL, but
not Mcl‐1, against Bcr‐Abl‐positive (Bcr‐Abl+) leukaemic cells was examined. ABT‐737 …

In this review, intratumoral drug disposition will be integrated into the wide range of
resistance mechanisms to anticancer agents with particular emphasis on targeted protein …

Abstract Increased levels of Bcr-Abl expression in chronic myelogenous leukemia (CML)
cells are associated with disease progression and imatinib (IM) resistance. However, it is not …

The BCR-ABL1 oncogenic tyrosine kinase can transform pluripotent hematopoietic stem
cells and initiate chronic myeloid leukemia in chronic phase (CML-CP), a myeloproliferative …

The introduction of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has
dramatically improved the treatment of chronic myeloid leukemia (CML). However, a minority …

Sphingolipids, such as ceramide, sphingosine and sphingosine 1-phosphate (S1P) are
bioactive molecules that have important functions in a variety of cellular processes, which …